PRPH2相关视网膜病变中黄斑新生血管抗VEGF治疗的长期结局
多中心回顾性病例系列纳入6例分子确诊的PRPH2相关视网膜病变合并单侧黄斑新生血管(MNV)患者,比较抗VEGF治疗眼与对侧眼的最佳矫正视力(BCVA)和中心子区厚度(CST)。中位随访6.2年、每人中位5.5次注射后,5眼(83%)BCVA保持至少20/32 Snellen,CST中位下降69 μm,未观察到治疗眼较对侧眼额外变薄;4眼(67%)OCT血管成像显示RPE下大型新生血管网在渗出消退后持续存在。作者认为及时玻璃体腔抗VEGF治疗可获得良好长期结局,RPE下新生血管网的意义需进一步研究。
要点
- 6例PRPH2相关视网膜病变合并单侧MNV患者中位发病年龄55岁,发现两种新发PRPH2变异。
- 中位随访6.2年、每人中位5.5次注射后,5眼(83%)BCVA保持至少20/32 Snellen。
- CST中位下降69 μm(范围-117至+15),治疗眼较对侧眼未见额外CST变薄。
核心结论
- 作者认为,PRPH2相关视网膜病变合并MNV时,及时玻璃体腔抗VEGF治疗可获得良好的长期功能与结构结局。
- 作者指出,需进一步研究以理解RPE下新生血管网的意义。
研究设计与样本
- 多中心回顾性病例系列,纳入分子确诊的PRPH2相关视网膜病变合并单侧MNV患者6例。
- 以BCVA和CST为结局指标,比较接受抗VEGF治疗的MNV眼与对侧眼。
主要发现
- 6例患者中位年龄55岁,发现两种新发PRPH2变异[c.499del p.(Cys150Phefs*3)、c.660dup p.(Pro221Alafs*80)]。
- 所有患者表型均为伴多发性斑点的图案状营养不良。
- 基线时MNV眼中位(范围)BCVA(logMAR)为0.2(0.2至0.7),对应20/32 Snellen;中位(范围)CST为320 μm(228至362)。
- 中位随访6.2年、每人中位5.5次注射后,5眼(83%)BCVA保持至少20/32 Snellen,CST中位(范围)下降69 μm(-117至+15)。
- MNV眼较对侧眼未观察到额外CST变薄;4眼(67%)OCT血管成像显示RPE下大型新生血管网在渗出消退后持续存在。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究以理解RPE下新生血管网的意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the long-term functional and structural outcomes of intravitreal anti-VEGF therapy for macular neovascularization (MNV) in PRPH2-associated retinopathy. METHODS: Multicenter retrospective case series including patients with molecularly confirmed PRPH2-associated retinopathy complicated by unilateral MNV. Best-corrected visual acuity (BCVA) and central subfield thickness (CST) were selected as outcome measures and compared between eyes with MNV undergoing anti-VEGF therapy and fellow eyes. RESULTS: Six patients affected by PRPH2-associated retinopathy had MNV at a median age of 55 years. Two novel PRPH2 variants were found [c.499del p.(Cys150Phefs*3), c.660dup p.(Pro221Alafs*80)]. In all patients the phenotype was characterized by a pattern dystrophy with multifocal flecks. At baseline, eyes with MNV had a median (range) BCVA (logMAR) of 0.2 (0.2 to 0.7), corresponding to 20/32 Snellen, while the median (range) CST was 320 μm (228 to 362). After a median follow-up of 6.2 years and 5.5 injections per patient, 5 (83%) eyes retained a BCVA of at least 20/32 Snellen, while CST decreased by a median (range) of -69 μm (-117 to +15). No additional CST thinning was observed in eyes with MNV compared to their fellow eyes. In 4 (67%) eyes, OCT angiography revealed large neovascular networks growing below the retinal pigment epithelium (RPE) that persisted after resolution of exudation. CONCLUSIONS: A favorable long-term outcome can be obtained in PRPH2-associated retinopathy complicated by MNV when timely intravitreal anti-VEGF therapy is administered. Further research is needed to understand the significance of sub-RPE neovascular networks.
引用
- Bianco L, Audo I, Antropoli A, et al. LONG-TERM OUTCOMES OF ANTI-VEGF THERAPY FOR MACULAR NEOVASCULARIZATION IN PRPH2-ASSOCIATED RETINOPATHY. Retina. 2025. PMID: 40184549. doi:10.1097/IAE.0000000000004476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。